| scholarly article | Q13442814 |
| P50 | author | Carmina Vidal | Q50718615 |
| P2093 | author name string | Juan Giles | |
| Jose Bellver | |||
| Pilar Alama | |||
| P2860 | cites work | Effects of luteinizing hormone and human chorionic gonadotropin on corpus luteum cells in a spheroid cell culture system | Q81834371 |
| Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A | Q82128728 | ||
| Ovarian hyperstimulation syndrome | Q82598907 | ||
| Blood group and ovarian hyperstimulation syndrome | Q84408996 | ||
| Gonadotrophin-releasing hormone antagonists for assisted reproductive technology | Q24234608 | ||
| Gonadotrophin-releasing hormone antagonists for assisted conception | Q24245006 | ||
| Vascular endothelial growth factor B, a novel growth factor for endothelial cells | Q24312842 | ||
| A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases | Q24336293 | ||
| Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor | Q24560244 | ||
| Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family | Q24604514 | ||
| Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis | Q28278251 | ||
| Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14 | Q28297843 | ||
| GnRH agonist for triggering of final oocyte maturation: time for a change of practice? | Q28308094 | ||
| Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation | Q31864785 | ||
| The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial | Q33731989 | ||
| Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome | Q33909727 | ||
| Preventive attitude of physicians to avoid OHSS in IVF patients | Q34451117 | ||
| Vascular endothelial growth factor: basic science and clinical progress | Q34549887 | ||
| Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome | Q34589955 | ||
| A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients | Q34700608 | ||
| Vascular permeability, vascular hyperpermeability and angiogenesis | Q34753662 | ||
| "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. | Q34758107 | ||
| Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial | Q34928751 | ||
| A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol | Q34997672 | ||
| Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review | Q35011448 | ||
| Regulation of vascular permeability by vascular endothelial growth factors. | Q35127972 | ||
| Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. | Q35139542 | ||
| Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study | Q48819444 | ||
| Distinction between early and late ovarian hyperstimulation syndrome | Q48891954 | ||
| Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study | Q48916300 | ||
| Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients | Q49040476 | ||
| Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors | Q49106751 | ||
| Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. | Q50643211 | ||
| Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. | Q50761764 | ||
| Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization | Q50792253 | ||
| Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. | Q51008884 | ||
| Some analogs of luteinizing hormone releasing hormone (LH-RH) having intense ovulation-inducing activity | Q53883566 | ||
| Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. | Q54787297 | ||
| Vascular Endothelial Growth Factor Receptor-2 Activation Induces Vascular Permeability in Hyperstimulated Rats, and this Effect Is Prevented by Receptor Blockade | Q59593526 | ||
| Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study | Q59676551 | ||
| Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? | Q67557694 | ||
| Disappearance of exogenously administered human chorionic gonadotropin | Q69721064 | ||
| Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! | Q73587450 | ||
| Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. | Q73942932 | ||
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | Q74247852 | ||
| Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells | Q74446280 | ||
| First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) | Q74476640 | ||
| Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent | Q74505681 | ||
| Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study | Q77664373 | ||
| [Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study] | Q80567510 | ||
| Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary | Q80961235 | ||
| Reproductive biology and IVF: ovarian stimulation and endometrial receptivity | Q35703626 | ||
| Can we eliminate severe ovarian hyperstimulation syndrome? | Q35965425 | ||
| Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis | Q36571890 | ||
| Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method | Q36630647 | ||
| Drugs in infertility and fetal safety | Q37179663 | ||
| Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study | Q37479046 | ||
| Preventing ovarian hyperstimulation syndrome: guidance for the clinician. | Q37736733 | ||
| An OHSS-Free Clinic by segmentation of IVF treatment | Q37914493 | ||
| Agonist and antagonist coast | Q37977630 | ||
| Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective | Q38160875 | ||
| A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation | Q38389752 | ||
| Ovarian hyperstimulation syndrome: an update review. | Q38645691 | ||
| Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications | Q41009148 | ||
| The pathophysiology of ovarian hyperstimulation syndrome--views and ideas | Q41530489 | ||
| Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome | Q41608623 | ||
| Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial | Q41609058 | ||
| Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method | Q41612191 | ||
| Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study | Q41612779 | ||
| Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles | Q42166546 | ||
| Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome | Q42166613 | ||
| Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study. | Q42971437 | ||
| Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome. | Q43073096 | ||
| Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting | Q43194352 | ||
| Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways | Q43222884 | ||
| GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study | Q43243450 | ||
| Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome | Q43543462 | ||
| Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles | Q43712296 | ||
| Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor | Q44055189 | ||
| Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos | Q44155781 | ||
| Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats | Q44799167 | ||
| Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes | Q45261097 | ||
| Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. | Q45927696 | ||
| Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists. | Q45942051 | ||
| 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study | Q46129525 | ||
| Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. | Q46161370 | ||
| Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol | Q46161375 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| Complications of medically assisted conception in 3,500 cycles | Q46415299 | ||
| A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists | Q46568123 | ||
| Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome | Q46592157 | ||
| Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization | Q46606124 | ||
| Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? | Q46695797 | ||
| In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols | Q46717670 | ||
| Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study | Q46962402 | ||
| Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist | Q46972539 | ||
| No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles | Q48747756 | ||
| A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. | Q48783410 | ||
| The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective | Q48794248 | ||
| Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction | Q48794435 | ||
| P433 | issue | 2 | |
| P921 | main subject | ovarian hyperstimulation syndrome | Q1760461 |
| P304 | page(s) | 107-116 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | International journal of endocrinology and metabolism | Q26842330 |
| P1476 | title | GnRH analogues in the prevention of ovarian hyperstimulation syndrome | |
| P478 | volume | 11 |
| Q26799866 | Comparison of different stimulation protocols used in in vitro fertilization: a review |
| Q33747432 | Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis. |
| Q39271823 | Epidemiology of critical states during pregnancy after assisted reproductive technologies |
Search more.